决奈达隆具有多通道阻滞的电生理特性。
It is a multichannel blocker with electrophysiological properties.
这些化合物在药物比如决奈达隆的合成中可以例如是有用的中间体。
Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone.
有两点需要注意：一是我们还没有决奈达隆和其他药物如胺碘酮的对照研究，因此在这一点上讨论决奈达隆的相对有效性非常困难；
There are two caveats. One is that we don't yet have a comparator study of dronedarone vs. other drugs like amiodarone, so talking about comparative efficacy is very difficult at this point.
在此之前一项针对心衰患者进行的研究显示，服用决奈达隆的患者死亡率是服用安慰剂组的两倍，因此FDA曾于2006年驳回该药的申请。
The FDA rejected the drug once before, in 2006, after a study in patients with heart failure showed that people in the Multaq group died at twice the rate of those in the placebo group.
在此之前一项针对心衰患者进行的研究显示，服用决奈达隆的患者死亡率是服用安慰剂组的两倍，因此FDA曾于2006年驳回该药的申请。
The FDA rejected the drug once before, in 2006, after a study in patients with heart failure showed that people in the Multaq group died at twice the rate of those in the placebo group.
应用推荐